Antithrombotic potential of polymer-coated stents eluting platelet glycoprotein IIb/IIIa receptor antibody

Circulation

Volumn 94, Issue 12, 1996, Pages 3311-3317

  Aggarwal, Rajesh K ^a,d   Ireland, Deborah C ^a   Azrin, Michael A ^b   Ezekowitz, Michael D ^c   De Bono, David P ^a   Gershlick, Anthony H ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b UNIVERSITY OF CONNECTICUT   (United States)

^c YALE UNIVERSITY   (United States)

^d FREEMAN HOSPITAL   (United Kingdom)

Author keywords

platelet aggregation inhibitors; stents; thrombosis

Indexed keywords

CELLULOSE; FIBRINOGEN RECEPTOR; MONOCLONAL ANTIBODY; POLYMER; RECEPTOR ANTIBODY;

ADSORPTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ILIAC ARTERY; MALE; NONHUMAN; OCCLUSION; PRIORITY JOURNAL; RABBIT; STENT; THROMBOCYTE ADHESION; THROMBOSIS;

EID: 0030482535     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.94.12.3311     Document Type: Article

References (41)

1. Nath FC, Muller DWM, Ellis SG, Rosenschein U, Chapekis A, Quain L, Zimmerman C, Topol EJ. Thrombosis of a flexible coil coronary stent: frequency, predictors and clinical outcome. J Am Coll Cardiol. 1993;21:622-627.
2. Foley JB, Brown RIG, Penn IM. Thrombosis and restenosis after slenting in failed angioplasty: comparison with elective stenting. Am Heart J. 1994;128:12-20.
3. Liu MW, Voorhees WD, Agrawal S, Dean LS, Roubin GS. Stratification of the risk of thrombosis after intracoronary stenting for threatened or acute closure complicating coronary balloon angioplasty: a Cook registry study. Am Heart J. 1995;130:8-13.
4. Morice MC, Amor M, Benveniste E, Bunouf P, Cribler A, Labrunie P, Masquet C, Petiteau PY. Coronary slenting without coumadin phase II, III, IV, V: predictors of major complications. Circulation. 1995;92(suppl I):I-795. Abstract.
5. Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, Emanuelsson H, Marco J, Legrand V, Materne P, Belardi J, Sigwart U, Colombo A, Goy JJ, van den Heuvel P, Delcan J, Morel M, for the Benestent Study Group. A comparison of balloon-expandable-stenl implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med. 1994;331:489-495.
6. Wong SC, Baim DS, Schatz RA, Teirstein PS, King SB III, Curry RC Jr, Heuser RR, Ellis SG, Cleman MW, Overlie P, Hirshfeld JW, Walker CM, Litvack F, Fish D, Brinker JA, Buchbinder M, Goldberg S, Chuang YC, Leon MB, for the Palmaz-Schatz Stent Study Group. Immediate results and late outcomes after stent implantation in saphenous vein graft lesions: the multicenter U.S. Palmaz-Schatz stent experience. J Am Coll Cardiol. 1995;26:704-712.
7. Schwartz RS, Murphy JG, Edwards WD, Holmes DR. Bioabsorbable, drug-eluting, intracoronary stents: design and future applications. In: Sigwart U, Frank GI, eds. Coronary Stents. Berlin, Germany: Springer Verlag; 1992:135-154.
8. Lambert TL, Dev V, Rechavia E, Forrester JS, Litvack F, Eigler NL. Localized arterial wall drug delivery from a polymer-coated removable metallic stent: kinetics, distribution, and bioavailability of forskolin. Circulation. 1994;90:1003-1011.
9. Aggarwal RK, More RS, Ezekowitz MD, de Bono DP, Gershlick AH. Stent-related thrombosis: a deep arterial injury, reduced flow model. Thromb Haemost. 1995;73:1331. Abstract.
10. Azrin MA, Ling FS, Chen Q, Pawashe A, Migliaccio F, Homer R, Todd M, Ezekowitz MD. Preparation, characterization, and evaluation of a monoclonal antibody against the rabbit platelet glycoprotein IIb/IIIa in an experimental angioplasty model. Circ Res. 1994;75: 268-277.
11. Ey PL, Prowse SJ, Jenkin CR. Isolation of pure IgG1, IgG2a and IgG2b immunoglobulins from mouse serum using protein A-sepharose. Immunochemistry. 1978;15:429-436.
12. Salacinski PRP, McLean C, Sykes JEC, Clement-Jones VV, Lowry PJ. Iodination of proteins, glycoproteins and peptides using a solid- phase oxidising agent 1,3,4,6-tetrachloro-3a,6a-diphenyl-glycouril (Iodogen). Anal Biochem. 1981;117:136-146.
13. 111In(-labelled human platelets: optimal method. Clin Sci. 1980;58:243-248.
14. Folts J. An in vivo model of experimental arterial stenosis, intimal damage and periodic thrombosis. Circulation. 1991:83(suppl IV): IV-3-IV-14.
15. Folts JD, Crowell EB, Rowe GG. Platelet aggregation in partially obstructed vessels and its elimination with aspirin. Circulation. 1976; 54:365-370.
16. Bush LR, Campbell WB, Buja M, Tilton GD, Willerson JT. Effects of the selective thromboxane synthetase inhibitor dazoxiben on variations in cyclic blood flow in stenosed canine coronary arteries. Circulation. 1984;69:1161-1170.
17. Yao SK, McNatt J, Benedict CR, Rosolowsky M, Anderson HV, Cui K, Maffrand JP, Campbell WB, Buja LM, Willerson JT. ADP plays an important role in mediating plalelet aggregation and cyclic flow variations in vivo in stenosed and endothelium-injured canine coronary arteries. Circ Res. 1992;70:39-48.
18. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med. 1995;332:1553-1559.
19. Simoons ML, de Boer MJ, van den Brand MJBM, van Miltenburg AJM, Hoorntje JCA, Heyndrickx GR, van der Wieken LR, de Bono D, Rutsch W, Schaible TF, Weisman HF, Klootwijk P, Nijssen KM, Stibbe J, de Feyter PJ, and the European Cooperative Study Group. Randomized trial of a GPIIb/IIIa platelet receptor blocker in refractory unstable angina. Circulation. 1994;89:596-603.
20. Konstantopoulos K, Kamat SG, Schafer AI, Banez EI, Jordan R, Kleiman NS, Hellums JD. Shear-induced platelet aggregation is inhibited by in vivo infusion of an anti-glycoprotein IIb/IIIa antibody fragment, c7E3 Fab, in patients undergoing coronary angioplasty. Circulation. 1995;91:1427-1431.
21. Tcheng JE, Harrington RA, Kottke-Marchant K, Kleiman NS, Ellis SG, Kereiakes DJ, Mick MJ, Navetta FI, Smith JE, Worley SJ, Miller JA, Joseph DM, Sigmon KN, Kitt MM, du Mée CP, Califf RM, Topol EJ, for the IMPACT Investigators. Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker integrelin in elective coronary intervention. Circulation. 1995;91:2151-2157.
22. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 1994;330:956-961.
23. Aguirre FV, Topol EJ, Ferguson JJ, Anderson K, Blankenship JC, Heuser RR, Sigmon K, Taylor M, Gottlieb R, Hanovich G, Rosenberg M, Donohue TJ, Weisman HF, Califf RM, for the EPIC Investigators. Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention. Circulation. 1995;91:2882-2890.
24. Neumann FJ, Gawaz M, Ott I, May A, Mossmer G, Schomig A. Prospeclive evalualion of haemostatic predictors of subacute stent thrombosis after coronary Palmaz-Schatz stenting. J Am Coll Cardial. 1996;27:15-21.
25. Tcheng JE, Ellis SG, George BS, Kereiakes DJ, Kleiman NS, Talley D, Wang AL, Weisman HF, Califf RM, Topol EJ. Pharmacodynamics of chimeric glycoprotein IIb/IIIa imegrin antiplalelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation. 1994; 90:1757-1764.
26. Jorgensen L, Grothe AC, Groves HM, Kinlough-Rathbone RL, Richardson M, Mustard JF. Sequence of cellular responses in rabbit aortas following one and two injuries with a balloon catheler. Br J Exp Pathol 1988;69:473-486.
27. Groves HM, Kinlough-Rathbone RL, Mustard JF. Development of nonthrombogenicity of injured rabbit aortas despite inhibition of platelet adherence. Arteriosclerosis. 1986;6:189-195.
28. Kleiman NS, Raizner AE, Jordan R, Wang AL, Norton D, Mace KF, Joshi A, Coller BS, Weisman HF. Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GPIIb/IIIa receptors. J Am Coll Cardiol. 1995;26:1665-1671.
29. Nunes GL, Hanson SR, King SB, Sahatjian RA, Scott NA. Local delivery of a synthetic antithrombin with a hydrogel-coated angioplasty balloon catheter inhibits platelet-dependent thrombosis. J Am Coll Cordial. 1994;23:1578-1583.
30. Azrin MA, Mitchel JF, Fram DB, Pedersen CA, Cartun RW, Barry JJ, Bow LM, Waters DD, McKay RG. Decreased platelet deposition and smooth muscle cell proliferation after intramural heparin delivery with hydrogel-coated balloons. Circulation. 1994;90:433-441.
31. Kemeny DM. The solid-phase support and the coaling antigen or antibody. In: Kemeny DM. A Practical Guide to ELISA. Oxford, UK: Pergamon Press; 1991:31-44.
32. Butler JE, Ni L, Nessler R, Joshi KS, Suter M, Rosenberg B, Chang J, Brown WR, Cantarero LA. The physical and functional behaviour of capture antibodies adsorbed on polystyrene. J Immunol Methods. 1992;150:77-90.
33. Amiji M, Park K. Surface modification of polymeric biomaterials with poly(ethylene oxide), albumin, and heparin for reduced thrombogenicity. J Biomater Sci Polym Ed. 1993;4:217-234.
34. Serruys PW, Emanuelsson H, van der Giessen W, Lunn AC, Kiemeney F, Macaya C, Rutsch W, Heyndrickx G, Suryapranata H, Legrand V, Goy JJ, Materne P, Bonnier H, Morice MC, Fajadet J, Belardi J, Colombo A, Garcia E, Ruygrok P, de Jaegere P, Morel MA, on behalf of the Benestent-II Study Group. Heparin-coated Palmaz-Schatz stems in human coronary arteries: early outcome of the Benestent-II pilot study. Circulation. 1996;93:412-422.
35. Weitz JI, Hudoba M, Mussel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithronibin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest. 1990;86:385-391.
36. Lane DA, Demon J, Flynn AM, Thunberg L, Lindahl U. Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4. Biochem J. 1984;218:725-732.
37. Lincoff AM, Topol EJ, Ellis SG, Local drug delivery for the prevention of restenosis: fact, fancy and future. Circulation. 1994;90: 2070-2084.
38. Matsuno H, Stassen JM, Vermylen J, Deckmyn H. Inhibition of integrin function by a cyclic RGD-containing peptide prevents neointima formation. Circulation. 1994;90:2203-2206.
39. 3 integrin with a small peptide antagonist GpenGRGDSPCA. J Vasc Surg. 1994;19:125-134.
40. Topol EJ, Califf RM, Weisman HF, Ellis SG, Tcheng JE, Worley S, Ivanhoe R, George BS, Fintel D, Western M, Sigmon K, Anderson KM, Lee KL, Willerson JT, on behalf of the EPIC investigators. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet. 1994;343:881-886.
41. Andrade JD, Hlady V. Plasma protein adsorption: the big twelve. Ann N Y Acad Sci. 1987;516:158-172.